Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 467 participants.

Also called NCT01076647

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 467 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01076647
  • EudraCT 2009-011399-31
Other papers using this trial's data
  • Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials The lancet. Diabetes & endocrinology, 2013-10 DOI, PubMed 24622318

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Bulgaria, Canada, France, Hungary, Netherlands, Romania (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01076647. Randomized; no masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2010-12 (actual). Results posted on 2015-11-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
Acronym
BEGIN™
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
insulin degludec
Intervention (Drug)
insulin glargine
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01076647
Content hash
35e2d5b7d54b3d243751cadadc193e6df0a3afffe310e6670e7cf2d29011c366